Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
16 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Prevenar 20 (previously Apexxnar)“
Suchtreffer
Begriffe & Kennungen
Prevenar 20 (previously Apexxnar) · 4.8 · Prevenar 20 was well tolerated, when administered in a 3-dose and a 4-dose series, in the infant study populat
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Safety with concomitant vaccine administration in adults
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Studies 1011, 1013 and 1003, were double-blind, randomised, active-controlled trials that included 2 232 healt
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Study 1012 was a pivotal, double-blind, randomised, active-controlled Phase 3 trial, in which 601 healthy infa
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Summary of the safety profile
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Table 1. Tabulated Adverse Reactions From Prevenar 20 Clinical Trials System Organ Adverse Reactions Frequency
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Table 2 includes adverse experiences that have been spontaneously reported during the postmarketing use of Pre
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Table 2. Adverse Reactions From Prevenar 13 Postmarketing Experience System Organ Class Frequency Not Known
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Tabulated lists of adverse reactions from the infant Phase 2, Phase 3 clinical trials in paediatric and adult
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · The most frequently reported (> 10%) adverse reactions observed after any dose of Prevenar 20 in participants
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · The safety of Prevenar 20 was evaluated in 4 552 participants 18 years of age and older in 6 clinical trials (
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · The safety of Prevenar 20 was evaluated in 5 987 participants, 6 weeks of age to less than 18 years of age, in
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · When Prevenar 20 was administered to adults aged ≥ 65 years together with the third (booster) dose of a COVID-
Eintrag öffnen